EXAI Investor Alert: Bronstein, Gewirtz & Grossman LLC announces that Exscientia plc investors with significant losses have the opportunity to pursue a class action lawsuit!

NEW YORK, May 8, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, informs investors that a class action lawsuit has been filed against Exscientia plc (“Exscientia” or “the.”). Company”) (NASDAQ: EXAI) and certain of its officers.

Class definition:

The purpose of this lawsuit is to recover damages against defendants for alleged violations of the federal securities laws on behalf of all individuals and entities that purchased or otherwise acquired Exscientia securities between March 23, 2022 and February 12, 2024 (including the “Class Period”) have. Such investors are encouraged to join this case by visiting the Company’s website: bgandg.com/EXAI.

Case details:

According to the complaint, Exscientia is an artificial intelligence (“AI”)-based pharmaceutical technology company engaged in the development and development of differentiated medicines for diseases with high unmet patient needs.

According to the complaint, the company purported at all relevant times to “adhere to the highest standards of business conduct and ethics” and, to that end, adopted a code of business conduct and ethics that applies to all of its employees, officers and directors, including the former chief Executive Officer (“CEO”) and Director, the Defendant Andrew Hopkins (“Hopkins”), the former Chairman of the Board of Directors of the Company (the “Board”), the Defendant David Nicholson (“Nicholson”), and all other officers and directors Employee.

The lawsuit alleges that defendants made materially false and misleading statements about the Company’s business, operations, and prospects throughout the Class Period. Specifically, Defendants made false and/or misleading statements and/or failed to disclose:

(1) Defendant Hopkins had engaged in inappropriate relationships with employees that were inconsistent with the Company’s standards and values;

(2) Defendant Nicholson already had knowledge of Defendant Hopkins’ relationships and had inappropriately addressed Hopkins’ misconduct without consulting the Board;

(3) the Company’s maintenance and enforcement of its code of business conduct and ethics was not sufficient to protect against the foregoing conduct;

(4) The foregoing failures exposed the Company to increased risk of disruptive leadership transitions and/or reputational damage; And

(5) As a result, Defendant’s public statements were materially false and/or misleading at all relevant times.

On February 13, 2024, Exscientia issued a press release in which it “announced that its Board of Directors (the ‘Board’) has decided to terminate the employment of (Defendant) Hopkins as (CEO) and Chief Executive Officer of the Company, and Dr. “To remove Hopkins from his role as Executive Director of the Board with cause and effective immediately.” The press release further revealed that the Board’s decision was made following an investigation that determined that defendant Hopkins “had relationships with two employees who, in the opinion of the board, were inappropriate and inconsistent with the company’s standards and values. Additionally, the press release stated that during the course of the investigation, the board learned that “(defendant) Nicholson (…) was already aware of the existence of Dr. Hopkins and had dealt with the situation directly.”, and with the involvement of other outside advisors, rather than in consultation with the board,” and “(f)ollowing discussions with the board, Dr. Nicholson tendered his resignation from his positions with the Company on February 12, 2024.”

According to the complaint, on this news, Exscientia’s stock price fell $1.72 per share, or 22.9%, closing at $5.79 per share on February 13, 2024.

According to the complaint, investors have suffered significant losses and damages due to defendants’ wrongful acts and omissions and the precipitous decline in the market value of the Company’s securities.

What’s next?

A class action lawsuit has already been filed. If you would like to review a copy of the Complaint, you may visit the Company’s website: bgandg.com/EXAI or you may contact Peretz Bronstein, Esq. turn around. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss with Exscientia, you have until June 25, 2024 to ask the Court to appoint you as lead plaintiff. Your ability to share in the recovery does not require you to serve as lead plaintiff.

There are no costs for you

We represent investors in class actions on a contingency fee basis. This means that we will only ask the court to reimburse us for our expenses and attorneys’ fees, usually a percentage of the total recovery, if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm representing investors in securities fraud class actions and shareholder derivative litigation. Our company has recovered hundreds of millions of dollars for investors nationwide.

Lawyer advertising. Previous results do not guarantee similar results.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller,

332-239-2660 | [email protected]

View original content to download multimedia: https://www.prnewswire.com/news-releases/exai-investor-alert-bronstein-gewirtz–grossman-llc-announces-that-exscientia-plc-investors-with -substantial-losses-have-the-possibility-of-leading-class-action-suit-302135175.html

SOURCE Bronstein, Gewirtz & Grossman, LLC